Table 1.
The FDA has approved a variety of new immunotherapies.
| Trade name | Generic name | Target | Disease | Approved by FDA |
|---|---|---|---|---|
| Provenge | Sipuleucel-T | PAP | Asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer | 2010.4 |
| Yervoy | Ipilimumab | CTLA-4 | Adult patients with inoperable or metastatic melanoma | 2011.3 |
| Pediatric patients aged 12 years and older with unresectable or metastatic melanoma | 2017.7 | |||
| Keytruda | Pembrolizumab | PD-1 | Advanced or unresectable melanoma | 2014.9 |
| Classic Hodgkin's lymphoma | 2017.3 | |||
| Recurrent or metastatic cervical cancer | 2018.6 | |||
| Blincyto | Blinatumomab | CD19, CD3 | B-cell precursor ALL | 2014.1 |
| MRD positive B cell precursor ALL | 2018.3 | |||
| Opdivo | Nivolumab | PD-1 | Advance melanoma | 2014.1 |
| NSCLC | 2015.3 | |||
| Colorectal cancer | 2017.8 | |||
| Tecentriq | Atezolizumab | PD-L1 | NSCLC | 2018.1 |
| First-line treatment for extensive stage small cell lung cancer | 2019.3 | |||
| Bavencio | Avelumab | PD-L1 | Metastatic MCC | 2017.3 |
| Locally advanced or metastatic urothelial carcinoma | 2017.5 | |||
| Imfinzi | Durvalumab | PD-L1 | Locally advanced or metastatic bladder carcinoma | 2017.5 |
| Stage 3 non-small cell lung cancer that is stable after surgery, chemotherapy, or radiation | 2018.2 | |||
| Kymriah | Tisagenlecleucel | CD19 | B-cell precursor ALL | 2017.8 |
| Yescarta | Axicabtagene Ciloleucel | CD19 | Adults with relapsed or refractory large B-cell lymphoma | 2017.1 |
| Opdivo & Yervoy | Nivolumab & Ipilimumab | PD-1, CTLA-4 | Intermediate and poor-risk advanced renal cell carcinoma | 2018.4 |
| Keytruda & Inlyta | Pembrolizumab & Axitinib | PD-1, VEGFR | Advanced RCC | 2019.4 |
PAP, prostate acid phosphatase; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; VEGFR, vascular endothelial growth factor receptor; ALL, acute lymphoblastic leukemia; MRD, minimal residual lesions; NSCLC, non-small cell lung cancer; MCC, Merkel cell carcinoma; RCC, renal cell carcinoma.